Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter.
Crit Care Explor
; 2(8): e0180, 2020 Aug.
Article
in English
| MEDLINE | ID: covidwho-703525
ABSTRACT
To determine whether Seraph-100 (Exthera Medical Corporation, Martinez, CA) treatment provides clinical benefit for severe coronavirus disease 2019 cases that require mechanical ventilation and vasopressor support. DATA SOURCES The first two patients in the United States treated with the novel Seraph-100 device. These cases were reviewed by the Food and Drug Administration prior to granting an emergency use authorization for treatment of coronavirus disease 2019. STUDY SELECTION Case series. DATA EXTRACTION Vasopressor dose, mean arterial pressure, temperature, interleukin-6, C-reactive protein, and other biomarker levels were documented both before and after Seraph-100 treatments. DATA SYNTHESIS:
Vasopressor dose, temperature, interleukin-6, and C-reactive protein levels declined after Seraph-100 treatments. Severe acute respiratory syndrome coronavirus 2 viremia was confirmed in the one patient tested and cleared by the completion of treatments.CONCLUSIONS:
Seraph-100 use may improve hemodynamic stability in coronavirus disease 2019 cases requiring mechanical ventilation and vasopressor support. These findings warrant future study of a larger cohort with the addition of mortality and total hospital day outcomes.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Reviews
Language:
English
Journal:
Crit Care Explor
Year:
2020
Document Type:
Article
Affiliation country:
CCE.0000000000000180
Similar
MEDLINE
...
LILACS
LIS